Protagen Protein Services GmbH (PPS), a full-service contract research organization (CRO) in protein analytics and BioAnalytix Inc., a Cambridge (MA)-based specialized provider of advanced analytics in biopharmaceutical development announced today a merger that will transform the combined company into a leading global analytic services provider for the biopharmaceutical industry.
Today’s announcement creates a best-in-class partner for biopharmaceutical companies worldwide to benefit from the most advanced, integrated and complete analytic services capabilities in biopharmaceutical development, from clone selection through drug approval to commercialization.
In working together with its pharmaceutical partners, the PPS and BioAnalytix teams generate best-in-class analytic data packages and provide scientific, technical and regulatory support to advance, de-risk and accelerate all stages of biopharmaceutical development at the highest of quality from clone through clinic.
Both companies have shared a similar vision, entrepreneurial agility and heritage of excellence in supporting leading pharmaceutical companies with high-end analytics and strategic solutions through development.
We are very excited to serve our pharma partners more directly in the FDA and EMEA territories, and continue our expansion in capacities and capabilities, now including BioAnalytix’s innovative areas such as advanced HDX-MS and in-vivo CQA Mapping.”
Martin Blüggel, Founder and CEO, PPS
We are thrilled about the combination of both companies and their analytic offerings. The broader platforms will enable us to provide a significantly greater range of analytic data packages and regulatory support here in the US as we expand our capabilities in advancing, de-risking and accelerating all stages of biotherapeutic development with our pharma partners.”
Kirtland Poss, Founder and CEO, BioAnalytix
By combining analytic platforms, programs and highly experienced analytic teams based both in US and in Europe, PPS and BioAnalytix will work directly and more broadly with leading biopharmaceutical companies in designing, generating and delivering integrated analytical data packages, and strategic support along the full development continuum, from developability and lead optimization, clone selection and process development, extended characterization and comparability, stability testing for control strategy design and CMC filings through commercialization and full GMP testing of commercial products.
Researchers discover how mutations disrupt protein splicing and cause disease